Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib + Docetaxel in 2nd Line NSCLC
NCT01750281Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2012
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of selumetinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Dec 2012; status: completed.
02
Drugs
selumetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01750281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01750281.